<DOC>
	<DOCNO>NCT02460692</DOCNO>
	<brief_summary>This study involve treat low back pain associate nerve injury oral delta-9-tetrahydrocannabinol ( Δ9-THC ) whole plant cannabis eight week . Research subject consume either oral Δ9-THC ( dronabinol ) , vaporize 3.7 % Δ9-THC/5.6 % CBD , placebo . An analysis determine assess risk -- benefit ratio dronabinol vaporize 3.7 % Δ9-THC/5.6 % CBD .</brief_summary>
	<brief_title>Trial Dronabinol Vaporized Cannabis Neuropathic Low Back Pain</brief_title>
	<detailed_description>The present study design ass whether treatment vaporize cannabis dronabinol ( oral Δ9-THC ) reduce spontaneous evoke pain placebo , whether difference two active treatment term interference activity daily live . This study also aim examine effect vaporize whole plant cannabis dronabinol mood , neuropsychological function , psychomimetic side-effects ( high , stone , etc . ) compare placebo . In addition , plan examine acute effect ( receive stable treatment 4 week ) vaporize cannabis dronabinol compare placebo drive skill .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Age great 18 . Presence chronic low back pain ( CLBP ) define response two question 1 ) How long back pain ongoing problem ? 2 ) How often low back pain ongoing problem past 6 month ? A response great 3 month question 1 response `` least half day past 6 month '' question 2 define CLBP accord NIH Task Force Research Standards Chronic Low Back Pain . The numerical pain intensity must great 3/10 day oneweek observation period . To avoid confound concurrent medication , participant stable analgesic regimen continue throughout study To obviate residual neuropsychological effect cannabis exposure , participant abstinent herbal medicine 7 day prior study entry . Presence another painful condition great severity neuropathic pain condition study . History traumatic brain injury . Clinically significant unstable medical condition . Individuals significant cardiovascular , hepatic renal disease , uncontrolled hypertension , chronic pulmonary disease ( eg , asthma , COPD ) , exclude . If warrant clinically , subject undergo laboratory evaluation ( blood chemistry , electrocardiogram , urinalysis , toxicology screen confirmation . Females childbearing potential undergo pregnancy test . A positive result toxicity screen exclude individual participation . A urine drug test screen 5 category drug : marijuana ( Δ9THC ) , cocaine , amphetamines/methamphetamines , opiate , benzodiazepine phencyclidine ( PCP ) employ . A positive result opioids and/or THC exclusionary patient receive prescription opioid and/or THC . Allergy sesame oil , lactose , gelatin Vascular disease , especially Raynauld 's syndrome , systolic blood pressure &gt; 170 mm , diastolic blood pressure &gt; 100 mm Recent injuries upper extremity Cognitive impairment , Dementia Alzheimer 's Disease Substance Abuse History : The Substance Abuse Module Diagnostic Interview Schedule DSMIV administer exclude individual current substance use disorder . Pregnancy ascertain mandatory commercial pregnancy test Past history suicide attempt . Cannabis exacerbate preexist schizophrenia , link increase risk suicide patient . In patient bipolar disorder , cannabis use associate worsen manic psychotic symptom . Such finding suggest cannabis contraindicate individual serious mental health issue , line reason observe present study exclude patient bipolar/schizoaffective/schizophrenic spectrum . Suicidality . Exposure cannabis lead depression may associate suicidal thought attempt . Therefore , BDIII use measure suicidal ideation .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>